×
BioCryst Pharmaceuticals Common Stock Net 2010-2024 | BCRX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
BioCryst Pharmaceuticals common stock net from 2010 to 2024. Common stock net can be defined as the value of common equity ownership.
View More
BioCryst Pharmaceuticals Common Stock Net 2010-2024 | BCRX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
BioCryst Pharmaceuticals common stock net from 2010 to 2024. Common stock net can be defined as the value of common equity ownership.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$79.8B
Takeda Pharmaceutical (TAK)
$42.6B
Sandoz Group AG (SDZNY)
$19.5B
Merck (MKKGY)
$19.1B
Astellas Pharma (ALPMY)
$18.3B
United Therapeutics (UTHR)
$16.6B
Summit Therapeutics (SMMT)
$14B
Neurocrine Biosciences (NBIX)
$12.7B
Shionogi (SGIOY)
$12B
Catalent (CTLT)
$11.1B
Madrigal Pharmaceuticals (MDGL)
$7.6B
Orion OYJ (ORINY)
$6.7B
Corcept Therapeutics (CORT)
$6B
Ionis Pharmaceuticals (IONS)
$5.4B
Crinetics Pharmaceuticals (CRNX)
$5.2B
PTC Therapeutics (PTCT)
$3.3B
Dyne Therapeutics (DYN)
$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.6B
Soleno Therapeutics (SLNO)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2.2B
NewAmsterdam Pharma (NAMS)
$1.9B
Xencor (XNCR)
$1.8B
Recursion Pharmaceuticals (RXRX)
$1.6B
Evotec AG (EVO)
$1.6B
Harrow (HROW)
$1.5B
Indivior (INDV)
$1.5B
Guardian Pharmacy Services (GRDN)
$1.5B
Ocular Therapeutix (OCUL)
$1.4B
ARS Pharmaceuticals (SPRY)
$1.4B